Pristimerin induces apoptosis by targeting the proteasome in prostate cancer cells

Journal of Cellular Biochemistry

Volumn 103, Issue 1, 2008, Pages 234-244

  Yang, Huanjie ^a   Landis Piwowar, Kristin R ^a   Lu, Dayan ^b   Yuan, Ping ^b   Li, Lihua ^a   Prem Veer Reddy, G ^a,c   Yuan, Xiao ^b   Dou, Q Ping ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INSTITUTE OF GEOLOGY AND GEOPHYSICS   (China)

^c HENRY FORD HOSPITAL   (United States)

Author keywords

Apoptosis; Natural compounds; Pristimerin; Prostate cancer; Proteasome inhibition

Indexed keywords

20S PROTEASOME; CHYMOTRYPSIN; HYDROXYL GROUP; I KAPPA B ALPHA; PRISTIMERIN; PROTEASOME; PROTEIN BAX; PROTEIN P27; THREONINE; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELASTRACEAE; CELL STRAIN LNCAP; COMPUTER MODEL; CONTROLLED STUDY; CULTURE MEDIUM; DRUG EFFECT; DRUG MECHANISM; DRUG STRUCTURE; ENZYME INHIBITION; HIPPOCRATEACEAE; HUMAN; HUMAN CELL; IC 50; MOLECULAR DOCKING; PRIORITY JOURNAL; PROSTATE CANCER; UBIQUITINATION;

ANDROGENS; ANIMALS; APOPTOSIS; CELL EXTRACTS; CELL LINE, TUMOR; COMPUTATIONAL BIOLOGY; ELECTRONS; HUMANS; KINETICS; MALE; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PROSTATIC NEOPLASMS; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN SUBUNITS; RABBITS; RECEPTORS, ANDROGEN; SERINE ENDOPEPTIDASES; TRITERPENES;

CELASTRACEAE; ORYCTOLAGUS CUNICULUS;

EID: 38149142504     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.21399     Document Type: Article

References (39)

1. Adams J. 2004. The development of proteasome inhibitors as anticancer drugs. Cancer Cell 5:417-421.
2. Adams J, Kauffman M. 2004. Development of the proteasome inhibitor Velcade (Bortezomib). Cancer Invest 22:304-311.
3. An B, Dou QP. 1996. Cleavage of retinoblastoma protein during apoptosis: An interleukin 1β-converting enzyme-like protease as candidate. Cancer Res 56:438-442.
4. An B, Goldfarb RH, Siman R, Dou QP. 1998. Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts. Cell Death Differ 5:1062-1075.
5. Ashkenazi A, Dixit VM. 1998. Death receptors: Signaling and modulation. Science 281:1305-1308.
6. Avilla J, Teixido A, Velazquez C, Alvarenga N, Ferro E, Canela R. 2000. Insecticidal activity of Maytenus species (Celastraceae) nortriterpene quinone methides against codling moth, Cydia pomonella (L.) (Lepidoptera: Tortricidae). J Agric Food Chem 48:88-92.
7. Buffa Filho W, Corsino J, Bolzani da SV, Furlan M, Pereira AM, Franca SC. 2002. Quantitative determination for cytotoxic Friedo-nor-oleanane derivatives from five morphological types of Maytenus ilicifolia (Celastraceae) by reverse-phase high-performance liquid chromatography. Phytochem Anal 13:75-78.
8. Chang FR, Hayashi K, Chen IH, Liaw CC, Bastow KF, Nakanishi Y, Nozaki H, Cragg GM, Wu YC, Lee KH. 2003. Antitumor agents. 228. Five new agarofurans, Reissantins A-E, and cytotoxic principles from Reissantia buchananii. J Nat Prod 66:1416-1420.
9. Chen ZJ, Hagler J, Palombella VJ, Melandri F, Scherer D, Ballard D, Maniatis T. 1995. Signal-induced site-specific phosphorylation targets IκBα to the ubiquitin-proteasome pathway. Genes Dev 9:1586-1597.
10. Chen D, Daniel KG, Chen MS, Kuhn DJ, Landis-Piwowar KR, Dou QP. 2005. Dietary flavonoids as proteasome inhibitors and apoptosis inducers in human leukemia cells. Biochem Pharmacol 69:1421-1432.
11. Daniel KG, Gupta P, Harbach RH, Guida WC, Dou QP. 2004. Organic copper complexes as a new class of proteasome inhibitors and apoptosis inducers in human cancer cells. Biochem Pharmacol 67:1139-1151.
12. Dirsch VM, Kiemer AK, Wagner H, Vollmar AM. 1997. The triterpenoid quinonemethide pristimerin inhibits induction of inducible nitric oxide synthase in murine macrophages. Eur J Pharmacol 336:211-217.
13. Dou QP, Smith DM, Daniel KG, Kazi A. 2003. Interruption of tumor cell cycle progression through proteasome inhibition: Implications for cancer therapy. Prog Cell Cycle Res 5:441-446.
14. Figueiredo JN, Raz B, Sequin U. 1998. Novel quinone methides from Salacia kraussii with in vitro antimalarial activity. J Nat Prod 61:718-723.
15. Goldberg AL. 1995. Functions of the proteasome: The lysis at the end of the tunnel. Science 268:522-523.
16. Green DR, Reed JC. 1998. Mitochondria and apoptosis. Science 281:1309-1312.
17. Gross A, McDonnell JM, Korsmeyer SJ. 1999a. BCL-2 family members and the mitochondria in apoptosis. Genes Dev 13:1899-1911.
18. Gross A, Yin XM, Wang K, Wei MC, Jockei J, Milliman C, Erdjument-Bromage H, Tempst P, Korsmeyer SJ. 1999b. Caspase cleaved BID targets mitochondria and is required for cytochrome c release, while BCL-XL prevents this release but not tumor necrosis factor-R1/Fas death. J Biol Chem 274:1156-1163.
19. Jenster G. 1999. The role of the androgen receptor in the development and progression of prostate cancer. Semin Oncol 26:407-421.
20. Kazi A, Daniel KG, Smith DM, Kumar NB, Dou QP. 2003. Inhibition of the proteasome activity, a novel mechanism associated with the tumor cell apoptosis-inducing ability of genistein. Biochem Pharmacol 66:965-976.
21. Lazebnik YA, Kaufmann SH, Desnoyers S, Poirier GG, Earnshaw WC. 1994. Cleavage of poly(ADP-ribose) polymerase by a proteinase with properties like ICE. Nature 371:346-347.
22. Li B, Dou QP. 2000. Bax degradation by the ubiquitin/proteasome-dependent pathway: Involvement in tumor survival and progression. Proc Natl Acad Sci USA 97:3850-3855.
23. Lin HK, Altuwaijri S, Lin WJ, Kan PY, Collins LL, Chang C. 2002. Proteasome activity is required for androgen receptor transcriptional activity via regulation of androgen receptor nuclear translocation and interaction with coregulators in prostate cancer cell. J Biol Chem 277:36570-36576.
24. Luo DQ, Wang H, Tian X, Shao HJ, Liu JK. 2005. Antifungal properties of pristimerin and celastrol isolated from Celastrus hypoleucus. Pest Manage Sci 61:85-90.
25. Nagata S. 1997. Apoptosis by death factor. Cell 88:355-365.
26. Nam S, Smith DM, Dou QP. 2001. Ester bond-containing tea polyphenols potently inhibit proteasome activity in vitro and in vivo. J Biol Chem 276:13322-13330.
27. Nandi D, Tahiliani P, Kumar A, Chandu D. 2006. The ubiquitin-proteasome system. J Biosci 31:137-155.
28. Newman DJ, Cragg GM, Snader KM. 2003. Natural products as sources of new drugs over the period 1981-2002. J Nat Prod 66:1022-1037.
29. Niampoka C, Suttisri R, Bavovada R, Takayama H, Aimi N. 2005. Potentially cytotoxic triterpenoids from the root bark of Siphonodon celastrineus Griff. Arch Pharm Res 28:546-549.
30. O'Connor OA, Wright J, Moskowitz C, Muzzy J, MacGregor-Cortelli B, Stubblefield M, Straus D, Portlock C, Hamlin P, Choi E, Dumetrescu O, Esseltine D, Trehu E, Adams J, Schenkein D, Zelenetz A. 2005. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol 23:676-684.
31. Orlowski M, Wilk S. 2000. Catalytic activities of the 20 S proteasome, a multicatalytic proteinase complex. Arch Biochem Biophys 383:1-16.
32. Orlowski RZ, Voorhees PM, Garcia RA, Hall MD, Kudrik FJ, Allred T, Johri AR, Jones PE, Ivanova A, Van Deventer HW, Gabriel DA, Shea TC, Mitchell BS, Adams J, Esseltine DL, Trehu EG, Green M, Lehman MJ, Natoli S, Collins JM, Lindley CM, Dees EC. 2005. Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. Blood 105:3058-3065.
33. Pagano M, Tam SW, Theodoras AM, Beer-Romero P, Del Sal G, Chau V, Yew PR, Draetta GF, Rolfe M. 1995. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 269:682-685.
34. Papandreou CN, Daliani DD, Nix D, Yang H, Madden T, Wang X, Pien CS, Millikan RE, Tu SM, Pagliaro L, Kim J, Adams J, Elliott P, Esseltine D, Petrusich A, Dieringer P, Perez C, Logothetis CJ. 2004. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol 22:2108-2121.
35. Sassa H, Kogure K, Takaishi Y, Terada H. 1994. Structural basis of potent ntiperoxidation activity of the triterpene celastrol in mitochondria: Effect of negative membrane surface charge on lipid peroxidation. Free Radic Biol Med 17:201-207.
36. Smith DM, Daniel KG, Wang Z, Guida WC, Chan TH, Dou QP. 2004. Docking studies and model development of tea polyphenol proteasome inhibitors: Applications to rational drug design. Proteins 54:58-70.
37. Steller H. 1995. Mechanisms and genes of cellular suicide. Science 267:1445-1449.
38. Wu CC, Chan ML, Chen WY, Tsai CY, Chang FR, Wu YC. 2005. Pristimerin induces caspase-dependent apoptosis in MDA-MB-231 cells via direct effects on mitochondria. Mol Cancer Ther 4:1277-1285.
39. Yang H, Chen D, Cui QC, Yuan X, Dou QP. 2006. Celastrol, a triterpene extracted from the Chinese "Thunder of God Vine," is a potent proteasome inhibitor and suppresses human prostate cancer growth in nude mice. Cancer Res 66:4758-4765.